Tags: IRA, Inflation, Big PharmaBy: Keren Lentschner
The Sanofi laboratory has announced a 78% price drop for its best-selling insulin in the United States.
The list of culprits fell on Wednesday.
They are 27 drugs, pinned by the White House, because the increase in their prices exceeded inflation in the 4th quarter of 2022. Pfizer is the last of the class, with 5 drugs concerned.
Laboratories will have to pay rebates to the US government.
These measures are part of the Inflation Reduction Act (IRA), passed last summer, which will gradually come into force in the United States by 2029. Legislation that is disrupting the pharmaceutical industry.
Although there has been much talk in Europe of the consequences of the IRA on the industry of the Old Continent, its health component has attracted less attention.
The ambition of the Biden Administration is to reduce inequalities in access to care in the United States, in particular by lowering drug prices while…
This article is for subscribers only.
You have 87% left to discover.
Want to read more?
Unlock all items immediately.
Without engagement.
TEST FOR €0.99
Already subscribed?
Login
